世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

アジア太平洋地域の血漿市場予測 2020-2028年

ASIA PACIFIC BLOOD PLASMA MARKET FORECAST 2020-2028

 

出版社 出版年月電子版価格 ページ数
Inkwood Research
インクウッドリサーチ
2020年4月US$1,250
シングルユーザライセンス(印刷不可PDF)
172

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

サマリー

この調査レポートはアジア太平洋地域の血漿市場を分析・予測したInkwood Researchの市場調査報告書です。

Overview

KEY FINDINGS

The Asia Pacific blood plasma market is predicted to record growth at a CAGR of 6.59% during the forecast period, 2020-2028. The rich presence of major countries that make significant contributions to the overall market is the prominent driver of market growth.

MARKET INSIGHTS

The countries analyzed in the Asia Pacific blood plasma market for further analysis include Indonesia, Thailand, Japan, India, Australia & New Zealand, Vietnam, China, South Korea, and the rest of Asia Pacific. Japan is considered to be one of the leaders in the Asia Pacific blood plasma market. Several organizations of the country manufacture and supply plasma products. The Japan Blood Products Organization was established in 2012 to ensure a steady, self-sufficient, and safe supply of reliable plasma-derived products. Such organizations encourage people to donate blood more frequently, thereby ensuring an adequate supply of blood plasma throughout the region. There has also been a significant rise in the geriatric population of the country. India offers a lucrative blood plasma market with huge growth opportunities. However, in countries like Australia, the accessibility restrictions in terms of domestic plasma, and the increasing demands, are hampering the growth of the market. But, according to the Australian Science Media Centre report of 2018, the country fares high when it comes to the number of reported rates of anterior cruciate ligament (ACL) injury and reconstruction. The platelet-rich plasma (PRP) therapy is beneficial for ACL reconstruction treatment. Such factors aid the growth of the market in Australia.

COMPETITIVE INSIGHTS

Some of the eminent companies leading the market are China Biologic Products, CSL Limited, Fusion Health Care, Green Cross Holdings Corporation, Grifols, etc.
Our report offerings include:
- Explore key findings of the overall market
- Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
- Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
- Market Segmentation cater to a thorough assessment of key segments with their market estimations
- Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
- Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
- Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
- Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments



目次

Table of Contents

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. MARKET DEFINITION
3.2. KEY DRIVERS
3.2.1. WIDESPREAD ACCEPTANCE OF IMMUNOGLOBULIN-BASED THERAPIES
3.2.2. GROWING USAGE OF ALBUMIN IN OTHER THERAPEUTIC AREAS
3.2.3. GROWING GERIATRIC POPULATION
3.2.4. RISING PREVALENCE OF ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
3.2.5. INCREASE IN THE PATIENT POOL FOR HEMOPHILIA TREATMENT
3.3. KEY RESTRAINTS
3.3.1. INCREASING USAGE OF RECOMBINANT PLASMA PRODUCTS IN THERAPEUTIC TREATMENTS
3.3.2. HIGH COSTS OF BLOOD PLASMA TREATMENTS
3.3.3. ADVERSE REACTIONS ASSOCIATED WITH POST-TRANSFUSION
3.3.4. SPREAD OF PATHOGENIC CONTAMINANTS
3.3.5. HIGH REGULATIONS IN THE MARKET
4. KEY ANALYTICS
4.1. PORTER’S FIVE FORCES ANALYSIS
4.1.1. THREAT OF NEW ENTRY
4.1.2. THREAT OF SUBSTITUTION
4.1.3. BUYER’S POWER
4.1.4. SUPPLIER’S POWER
4.1.5. COMPETITIVE RIVALRY
4.2. PLASMA THERAPEUTICS REGULATION
4.3. CLINICAL GUIDELINES
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
4.6. KEY INVESTMENT INSIGHTS
5. MARKET BY MODE OF DELIVERY
5.1. INFUSION SOLUTIONS
5.2. GELS
5.3. SPRAYS
5.4. BIOMEDICAL SEALANTS
6. MARKET BY DISORDER
6.1. IMMUNODEFICIENCY DISEASE
6.2. HYPOGAMMAGLOBULINEMIA
6.3. HEMOPHILIA
6.4. VON WILLEBRAND DISEASE (VWD)
6.5. OTHER DISORDERS
7. MARKET BY BLOOD PLASMA DERIVATIVES
7.1. IMMUNOGLOBULIN
7.1.1. INTRAVENOUS IMMUNOGLOBULIN
7.1.2. SUBCUTANEOUS IMMUNOGLOBULIN
7.1.3. OTHER IMMUNOGLOBULIN TYPES
7.2. ALBUMIN
7.3. HYPERIMMUNE
7.4. COAGULATION FACTOR CONCENTRATES
7.5. OTHER PLASMA FRACTIONATION PRODUCTS
8. MARKET BY THERAPEUTIC INDICATION
8.1. NEUROLOGY
8.2. IMMUNOLOGY
8.3. ONCOLOGY
8.4. TRANSPLANTATION
8.5. HEMATOLOGY
8.6. RHEUMATOLOGY
8.7. PULMONOLOGY
8.8. OTHER THERAPEUTIC INDICATION
9. MARKET BY END-USER
9.1. HOSPITALS AND CLINICS
9.2. RESEARCH LABORATORIES
9.3. ACADEMIC INSTITUTIONS
10. GEOGRAPHICAL ANALYSIS
10.1. ASIA PACIFIC
10.1.1. JAPAN
10.1.2. CHINA
10.1.3. AUSTRALIA & NEW ZEALAND
10.1.4. INDIA
10.1.5. SOUTH KOREA
10.1.6. THAILAND
10.1.7. INDONESIA
10.1.8. VIETNAM
10.1.9. REST OF ASIA PACIFIC
11. COMPANY PROFILES
11.1. ADMA BIOLOGICS
11.2. ARTHREX
11.3. BIO PRODUCTS LABORATORY
11.4. BAXTER INTERNATIONAL
11.5. BIOTEST AG
11.6. CERUS CORPORATION (CERUS)
11.7. CHINA BIOLOGIC PRODUCTS
11.8. CSL LIMITED
11.9. FUSION HEALTH CARE
11.10. GREEN CROSS HOLDINGS CORPORATION
11.11. GRIFOLS
11.12. LFB
11.13. OCTAPHARMA
11.14. TAKEDA PHARMACEUTICAL COMPANY
11.15. KEDRION BIOPHARMA INC

List of Tables

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT - BLOOD PLASMA
TABLE 2: ASIA PACIFIC BLOOD PLASMA MARKET, BY DISORDER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 3: ASIA PACIFIC BLOOD PLASMA MARKET, BY DISORDER, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 4: ASIA PACIFIC BLOOD PLASMA MARKET, BY BLOOD DERIVATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 5: ASIA PACIFIC BLOOD PLASMA MARKET, BY BLOOD DERIVATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 6: ASIA PACIFIC BLOOD PLASMA MARKET, BY THERAPEUTIC INDICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 7: ASIA PACIFIC BLOOD PLASMA MARKET, BY THERAPEUTIC INDICATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 8: ASIA PACIFIC BLOOD PLASMA MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 9: ASIA PACIFIC BLOOD PLASMA MARKET, BY END-USER, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 10: ASIA PACIFIC BLOOD PLASMA, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 11: ASIA PACIFIC BLOOD PLASMA, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

Companies Mentioned

LIST OF FIGURES
FIGURE 1: PORTER’S FIVE FORCE ANALYSIS
FIGURE 2: OPPORTUNITY MATRIX
FIGURE 3: VENDOR LANDSCAPE
FIGURE 4: KEY INVESTMENT INSIGHTS
FIGURE 5: IMMUNOGLOBULIN INFUSIONS SIDE EFFECTS
FIGURE 6: ROLE OF FIBRIN SEALANT IN COAGULATION CASCADE
FIGURE 7: ASIA PACIFIC BLOOD PLASMA MARKET, BY DISORDER, IN 2019
FIGURE 8: ASIA PACIFIC BLOOD PLASMA MARKET, BY IMMUNODEFICIENCY DISEASE, 2020-2028 (IN $ MILLION)
FIGURE 9: ASIA PACIFIC BLOOD PLASMA MARKET, BY HYPOGAMMAGLOBULINEMIA, 2020-2028 (IN $ MILLION)
FIGURE 10: ASIA PACIFIC BLOOD PLASMA MARKET, BY HEMOPHILIA, 2020-2028 (IN $ MILLION)
FIGURE 11: ASIA PACIFIC BLOOD PLASMA MARKET, BY VON WILLEBRAND DISEASE (VWD), 2020-2028 (IN $ MILLION)
FIGURE 12: ASIA PACIFIC BLOOD PLASMA MARKET, BY OTHER DISORDERS, 2020-2028 (IN $ MILLION)
FIGURE 13: ASIA PACIFIC BLOOD PLASMA MARKET, BY BLOOD DERIVATIVES, IN 2019
FIGURE 14: ASIA PACIFIC BLOOD PLASMA MARKET, BY IMMUNOGLOBULIN, 2020-2028 (IN $ MILLION)
FIGURE 15: ASIA PACIFIC IMMUNOGLOBULIN MARKET, BY INTRAVENOUS IMMUNOGLOBULIN, 2020-2028 (IN $ MILLION)
FIGURE 16: ASIA PACIFIC IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS IMMUNOGLOBULIN, 2020-2028 (IN $ MILLION)
FIGURE 17: ASIA PACIFIC IMMUNOGLOBULIN MARKET, BY OTHER IMMUNOGLOBULIN TYPES, 2020-2028 (IN $ MILLION)
FIGURE 18: ASIA PACIFIC BLOOD PLASMA MARKET, BY ALBUMIN, 2020-2028 (IN $ MILLION)
FIGURE 19: ASIA PACIFIC BLOOD PLASMA MARKET, BY HYPERIMMUNE, 2020-2028 (IN $ MILLION)
FIGURE 20: HYPERIMMUNES ISOLATION PROCESS
FIGURE 21: ASIA PACIFIC BLOOD PLASMA MARKET, BY COAGULATION FACTOR CONCENTRATES, 2020-2028 (IN $ MILLION)
FIGURE 22: ASIA PACIFIC BLOOD PLASMA MARKET, BY OTHER PLASMA FRACTIONATION PRODUCTS, 2020-2028 (IN $ MILLION)
FIGURE 23: ASIA PACIFIC BLOOD PLASMA MARKET, BY THERAPEUTIC INDICATION, IN 2019
FIGURE 24: ASIA PACIFIC BLOOD PLASMA MARKET, BY NEUROLOGY, 2020-2028 (IN $ MILLION)
FIGURE 25: ASIA PACIFIC BLOOD PLASMA MARKET, BY IMMUNOLOGY, 2020-2028 (IN $ MILLION)
FIGURE 26: ASIA PACIFIC BLOOD PLASMA MARKET, BY ONCOLOGY, 2020-2028 (IN $ MILLION)
FIGURE 27: ASIA PACIFIC BLOOD PLASMA MARKET, BY TRANSPLANTATION, 2020-2028 (IN $ MILLION)
FIGURE 28: ASIA PACIFIC BLOOD PLASMA MARKET, BY HEMATOLOGY, 2020-2028 (IN $ MILLION)
FIGURE 29: ASIA PACIFIC BLOOD PLASMA MARKET, BY RHEUMATOLOGY, 2020-2028 (IN $ MILLION)
FIGURE 30: LUPUS INFECTION SYMPTOMS
FIGURE 31: ASIA PACIFIC BLOOD PLASMA MARKET, BY PULMONOLOGY, 2020-2028 (IN $ MILLION)
FIGURE 32: ASIA PACIFIC BLOOD PLASMA MARKET, BY OTHER THERAPEUTIC INDICATION, 2020-2028 (IN $ MILLION)
FIGURE 33: ASIA PACIFIC BLOOD PLASMA MARKET, BY END-USER, IN 2019
FIGURE 34: ASIA PACIFIC BLOOD PLASMA MARKET, BY HOSPITALS AND CLINICS, 2020-2028 (IN $ MILLION)
FIGURE 35: ASIA PACIFIC BLOOD PLASMA MARKET, BY RESEARCH LABORATORIES, 2020-2028 (IN $ MILLION)
FIGURE 36: ASIA PACIFIC BLOOD PLASMA MARKET, BY ACADEMIC INSTITUTIONS, 2020-2028 (IN $ MILLION)
FIGURE 37: ASIA PACIFIC BLOOD PLASMA MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
FIGURE 38: JAPAN BLOOD PLASMA, 2020-2028 (IN $ MILLION)
FIGURE 39: CHINA BLOOD PLASMA, 2020-2028 (IN $ MILLION)
FIGURE 40: AUSTRALIA & NEW ZEALAND BLOOD PLASMA, 2020-2028 (IN $ MILLION)
FIGURE 41: INDIA BLOOD PLASMA, 2020-2028 (IN $ MILLION)
FIGURE 42: SOUTH KOREA BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
FIGURE 43: THAILAND BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
FIGURE 44: INDONESIA BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
FIGURE 45: VIETNAM BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
FIGURE 46: REST OF ASIA PACIFIC BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る